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Abstract: Species identification by using matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) is a routine diagnostic process for infectious diseases in current
clinical settings. The rapid, low-cost, and simple to conduct methodology is expanding its application
in clinical microbiology laboratories to diagnose the antimicrobial resistance (AMR) in microorgan-
isms. Primarily, antimicrobial susceptibility testing is able to be carried out either by comparing
the area under curve of MALDI spectra of bacteria grown in media with antimicrobial drugs or
by identifying the shift peaks of bacteria grown in media including 13C isotope with antimicrobial
drugs. Secondly, the antimicrobial resistance is able to be determined through identifying (i) the
antimicrobial-resistant clonal groups based on the fingerprints of the clone, (ii) the shift peak of the
modified antimicrobial drug, which is inactivated by the resistance determinant, (iii) the shift peak of
the modified antimicrobial target, (iv) the peak specific for the antimicrobial determinant, and (v) the
biomarkers that are coproduced proteins with AMR determinants. This review aims to present the
current usage of the MALDI-TOF MS technique for diagnosing antimicrobial resistance in bacteria,
varied approaches for AMR diagnostics using the methodology, and the future applications of the
methods for the accurate and rapid identification of AMR in infection-causing bacterial pathogens.
Keywords: MALDI-TOF MS; antimicrobial resistance; rapid diagnostics
1. Introduction
Antimicrobial drugs have extended the human lifespan by saving lives from acquiring
infectious diseases [1]. However, drug usage has resulted in a drastic increase in antimi-
crobial resistance (AMR), including the emergence of resistance to multiple antimicrobial
drugs; therefore, the rapid and accurate diagnosis of antimicrobial susceptibility is encour-
aged to optimize the therapeutic strategy for patients with infectious diseases and control
infection in healthcare settings [2]. In terms of the AMR of infection-causing bacteria,
physicians need at least three pieces of information from clinical microbiology laboratories:
(i) whether the patient is infected by bacteria, (ii) if so, with which bacterial species, and
(iii) which antimicrobial regimen will treat the infection [3]. Rapid and accurate diagnostics
help physicians choose an appropriate drug regimen promptly, improve patient outcomes,
decrease patient hospitalization duration, and reduce the potential for pathogen spread [4].
The gold standards of antimicrobial susceptibility testing (AST) are based on bacterial
growth methods that determine the inhibition zone diameter around antimicrobial disks
on an agar surface or the minimum inhibitory concentration of an antimicrobial drug [5]
following the guidelines standardized by the Clinical Laboratory Standards Institutes
(USA), the British Society for Antimicrobial Chemotherapy (UK), la Société Française de
Microbiologie (France), the European committee on Antimicrobial Susceptibility Testing
(EU), etc. The primary defect of these methods is that it takes days to produce results,
which impedes the rapid elaboration of proper treatment strategies for the patient. The
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identification of AMR determinants, mostly based on genotype-determining molecular
biological methodologies, also has several limitations. First, the genotype does not always
correspond to the phenotype [6]. Some AMR genes need to be induced for expression,
and certain, but not rare, genetic alterations block the proper production of the particular
protein(s) that confer resistance to the antimicrobial drug. Second, detection of new,
emerging AMR determinants is impractical by genotyping. Third, coupling the AMR
genotype with the AMR phenotype of a bacterial strain requires a deep understanding
of the field [7], which means that this methodology needs experienced experts for data
interpretation. Finally, the technique is laborious and cost-inefficient, which impedes its
wide use in clinical microbiology laboratories.
Among the various techniques that have been suggested for rapid AMR diagnostics,
the matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF MS) method, which is already widely used in clinical settings for the rapid species
identification of organisms with medical importance, has been considered a supplement
for the growth-based AST [8]. This review aims to show varied approaches of MALDI-TOF
MS to rapidly determine AMR and develop an optimal treatment strategy for patients with
infectious diseases.
2. Application of MALDI-TOF MS in Clinical Microbiology Laboratories
The identification of bacterial species based on peptide spectra obtained from mass
spectrometry (MS) was first proposed in the 1970s [9]. However, directly exposing the
fragile bacterial samples to a powerful laser for desorption and ionization of the sample was
a challenging step that needed improvement. In the mid-1980s, Koichi Tanaka developed a
soft desorption ionization method using ultrafine metal powder and glycerol that enabled
MS analysis of biological macromolecules [10], and he was awarded the Nobel Prize in
Chemistry in 2002 for this work. Quite coincidently, Franz Hillenkamp and Michael Karas
reported another soft desorption ionization methodology using an organic compound ma-
trix [11] and finally, the matrix-assisted laser desorption ionization (MALDI) methodology
was conceived. MALDI-TOF MS was successfully introduced in clinical laboratories in the
early 2000s as a tool to identify particular species of organisms based on speed (less than a
minute per sample) and accurate identification of clinically relevant pathogens, especially
bacteria and fungi, with cost-effective benefits. Currently, the method of applying bacterial
and fungal colonies directly onto a MALDI target plate with matrices for cocrystallization
has become the standard protocol for the identification of bacterial and fungal species in
clinical laboratories [12].
The matrices consist of crystallizable molecules as a mixed solution in water or organic
solvents. Various matrix compounds are now available, and additional compounds are
under development [13] with three indispensable requisites: (i) having an appropriate
molecular weight, which is low enough to ensure easy vaporization and large enough not
to be entirely evaporated in the vacuum separation tube while standing in the apparatus,
(ii) having a strong optical absorption in either the ultraviolet or infrared region to absorb
laser irradiation rapidly and efficiently, and (iii) being an excellent proton donor that drives
the ionization of the analyte. Basically, the matrix plays two roles, both as a helper for
crystallization for efficient ionization and as a buffer between the sample and the powerful
laser. The sample entrapped within the matrix is cocrystallized with the matrix, and the
energy is applied to the sample as a laser beam to ionize the analyte, generating separate
protonated ions. These ions are accelerated at a fixed potential and separated from each
other on the basis of their weight during flight along the flight tube. The time of flight is
measured by determining the time to reach the detection panel at the end of the flight tube
(Figure 1).
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flight tube. 
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fication method in clinical laboratories, biochemical tests were used for the identification 
of bacteria and fungi. The process is very complex and requires multiple steps. Moreover, 
the method needs an individualized approach by organism type, and the results are often 
ambiguous. Clinical microbiologists need to be trained to conscientiously perform and 
interpret the colony phenotypes and Gram-stain morphology of bacteria growing on solid 
media to determine the appropriate biochemical tests and additional core gene DNA se-
quencing. However, through the application of MALDI-TOF MS, most of the colonies are 
directly applied for identification devoid of any preparation steps, and accurate identifi-
cation is available in minutes without experiential knowledge. In addition, with a few 
exceptions of hazardous organisms requiring careful handling, complex decision-making 
processes are not required. Testing can be performed from a single colony on primary 
culture plates. Complicated DNA sequencing and its expenses are avoided for organism 
identification, the amount of waste decreases, and training of laboratory technicians and 
excess labor are eliminated. 
A decade of MALDI-TOF MS experience with bacterial species identification in a 
clinical microbiology laboratory has indicated the following three efficiencies of this 
method compared to traditional biochemical methods [15]. MALDI-TOF MS and tradi-
tional biochemical methods are able to identify 36 and 19 bacterial species per 10000 iso-
lates, respectively. Supplemental genotypic identification using 16S rRNA sequences is 
required for 4.5 and 35.2 isolates per 10000 isolates with MALDI-TOF MS and biochemical 
methods, respectively. Finally, MALDI-TOF MS reduced the time for identification by 55-
fold and the cost by 5-fold compared with biochemical tests. 
Culture-independent direct application of clinical specimens to MALDI-TOF MS 
analysis to identify the infection-causing pathogen has been regarded as impractical be-
cause of the various extra molecules that can inhibit the ability to obtain clear spectra de-
rived from the pathogen. However, direct application of urine specimens to MALDI-TOF 
MS after simple processing has become possible, owing to the high concentration of bac-
teria in these specimens [16]. Polymicrobial infections [17] and abundant proteins of hu-
man origin in urine specimens, such as the antimicrobial peptides α-defensins, which are 
released from neutrophils to eliminate urinary tract infections [18], have been the major 
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MALDI-TOF MS has become a welcome addition to routine microbiology laboratory
practice. The most widely used analytical strategy using this technique is analysis of the
fingerprint spectra in the range of 2000 to 20000 m/z, reflecting the composite proteome of
a bacterial cell [14]. The identification of an infection-causing microorganism is possible
through this methodology. Before the introduction of the MALDI-TOF MS-based identifi-
cation method in clinical laboratories, biochemical tests were used for the identification of
bacteria and fungi. The process is very complex and requires multiple steps. Moreover,
the method needs an individualized approach by organism type, and the results are often
ambiguous. Clinical microbiologists need to be trained to conscientiously perform and
interpret the colony phenotypes and Gram-stain morphology of bacteria growing on solid
media to determine the appropriate biochemical tests and additional co gen DNA se-
quencing. H wever, through the application f MALDI-TOF MS, most f the colonies are
directly applied for identification devoid of any preparation steps, and accurate identi-
fication is available in minutes without experiential knowledge. In addition, with a few
exceptions of hazardous organisms requiring careful handling, complex decision-making
processes are not required. Testing can be performed from a single colony on primary
culture plates. Complicated DNA sequencing and its expenses are avoided for organism
identification, the amount of waste decreases, and trai ing of laboratory technicians and
excess labor are eliminated.
A decade of MALDI-TOF MS experience with bacterial species identification in a clini-
cal microbiology laboratory has indicated the following three efficiencies of this method
compared to traditional biochemical methods [15]. MALDI-TOF MS and traditional bio-
chemical methods are able to identify 36 and 19 bacterial species per 10000 isolates, respec-
tively. Supplemental genotypic identification using 16S rRNA sequences is required for
4.5 and 35.2 isolates per 10000 isolates with MALDI-TOF MS a d biochemical methods,
respectively. Finally, MALDI-TOF MS reduced the time for identification by 55-fold and
the cost by 5-fold compared with biochemical tests.
Culture-independent direct application of clinical specimens to MALDI-TOF MS anal-
ysis to identify the infection-causing pathogen has been regarded as impractical because of
the various extra molecules that can inhibit the ability to obtain clear spectra derived from
the pathogen. However, direct application of urine specimens to MALDI-TOF MS after
simple processing has become possible, owing to the high conce ration f bacteria in these
specimens [16]. Polymicrobial infections [17] and abundant proteins of human origin in
urine specimens, such as the antimicrobial peptides α-defensins, which are released from
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neutrophils to eliminate urinary tract infections [18], have been the major limitations of
the direct application of urine specimens. Various processing methods to prepare urine
specimens suitable for MALDI-TOF MS analysis have thus been proposed [19] and are still
under development. The direct MALDI-TOF MS application of clinical specimens other
than urine, such as cerebrospinal fluid [19,20] and blood [21], has also been attempted and
has presented results that seem not feasible, but possible.
3. AST by Using the MALDI-TOF MS
The major limitations of growth-based AST, which have time and labor dependencies,
have been considered to be solved by using the MALDI-TOF MS-based approach. A micro-
droplet assay, Direct-on-Target Microdroplet Growth Assay, was developed to overcome
the weak point of the traditional AST method by using MALDI-TOF MS [22]. Basically,
this method is based on comparative analysis of the spectral intensity of bacteria grown in
a droplet-amount of media with or without an antimicrobial drug. Reduction in intensity
after drug administration compared to that in the absence of drug is assumed to be the
antimicrobial drug susceptibility [23].
An approach using isotope-labeled nutrients, usually 13C-labeled amino acids, has
been able to give clear results by shift spectra [24,25]. Commercial media composed of
98% 13C or isotope-labeled lysine (13C615N2-L-lysine) have been used for the methods.
Bacterial growth of an isolate is monitored by the MALDI spectrum after a few hours of
incubation of the isolate in the labeled medium with or without an antimicrobial. Com-
parative analysis of the numbers and intensities of the isotope-mediated shift peaks after
growth without the antimicrobial drug to those after growth with the drug may explain
drug susceptibility.
These methods were developed as an alternative method for manual AST; however,
a few limitations remain. These include finding a proper single concentration of each
antimicrobial drug for testing for each bacterial species, optimization of both a universal
inoculum size and a universal incubation time for each bacterial species, and removal of
the liquid medium with the least amount of loss of the biomass.
4. Detecting the Antimicrobial Resistance
4.1. Identification of Antimicrobial-Resistant Clonal Groups
As a coherent approach for species identification of microorganisms through the whole-
cell proteome, MALDI-TOF MS using protein fingerprints of well-known antimicrobial-
resistant clonal groups has been attempted (Figure 2). Basically, this strategy is achievable
by means of the concept of bottom-up proteomics using a very large set of bacterial strains.
The most successful results to detect the antimicrobial-resistant clonal group were
achieved with Bacteroides fragilis [26]. This species is an important Gram-negative anaerobic
pathogen, and a cluster of B. fragilis, the so-called division II, carries the cfiA gene encoding
a metallo-beta-lactamase (MBL). The intrinsic gene is overexpressed when an insertion
sequence is integrated upstream of the gene, providing a strong promoter. Then, CfiA MBL
confers resistance against nearly all beta-lactam drugs to the bacterial host. Through an
extensive screening of B. fragilis, the cfiA-positive division II strains were distinguished
from the cfiA-negative strains by spectral shifts between 4000–5500 m/z, and the results
were satisfactory.
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Distinguishing methicillin-resistant Staphylococcus aureus (MRSA) from methicillin-
susceptible S. aureus (MSSA) is a matter of popular interest. One of the common strain-
typing methods, multilocus sequence typing (MLST), is closely associated with Staphy-
lococcal c ssette chromosome m c (SCCmec) types, including the mecA gene in MRSA.
Since MRSA clones of pecific sequence types are closely a sociated with certain types
of SCCmec, clonal grouping by using the whole-cell proteome spectral fingerprints by
MALDI-TOF MS was carried out [27]. Most of the epidemic MRSA isolates that cause
human infection belong to specific MLST clonal complexes (CCs), including CC5, CC8,
CC22, CC30, and CC45 [27,28], and CC97 and CC398 have been identified in MRSA in-
fections associated with livestock [29]. Thirteen characteristic peaks in the MALDI-TOF
MS spectrum have been reported to be useful to distinguish MRSA from MSSA [30]. A
study to distinguish between the MRSA groups of SCCmec types I–III, which are usually
associated with hospital-associated infections, from those of SCCmec types IV and V, which
are usually associated with community-associated infections, was carried out using a
group-specific peak in the range of 1000–4000 m/z, and peaks at 1772 m/z and 1792 m/z
from the phenol-soluble portion were identified as being specific for the former MRSA
clones [31].
Vancomycin-resistant Enter coccus (VRE) was another ta get for id ntification through
this strategy. The vanA gene-carrying Enterococcus faecium clinical strains, which are clus-
tered into a group via a programmed algorithm based on the MALDI-TOF MS spectra, were
detectable; however, this could not be demonstrated again in other studies [32]. Detection
of the vanB gene-carrying VRE lineage was attempted by comparing the MALDI-TOF MS
spectra with WGS data [33]. Similar to vanA-type VRE, this discriminatory power has
never been d monstrated in another study, even though the methodology was proven
thr ugh external validation with great diagnostic power, meaning that he detected VREs
in the study were endemic clones in the region.
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In addition, vancomycin-intermediate S. aureus (VISA) [34], MRSA [35], and carbapenem-
resistant Klebsiella pneumoniae [36] were also subjected to studies to identify AMR through
clonal lineage detection, often using machine learning technology [37]. However, none of
these studies have been proven to be useful to the public.
4.2. Identification of a Modified Antimicrobial Drug
AMR in bacteria is often conferred by enzymes that inactivate antimicrobial drugs,
either by hydrolyzing or by transferring acyl, phosphoryl, thiol, nucleotidyl, ADP-ribosyl,
and/or glycosyl groups to the drug. Enzymes with hydrolysis activity, which need water
as a cosubstrate, are beta-lactamases and macrolide esterases [38]. Additionally, the trans-
ferase enzyme group is composed of six enzymes depending on the group to be transferred,
i.e., acyltransferases, phosphotransferases, thioltransferases, nucleotidyltransferases, ADP-
ribosyltransferases, and glycosyltransferases [38]. As the modified antimicrobial drugs
change their molecular weights through the molecules added, antimicrobial resistance is
able to be identified by detecting the peak shift using the MALDI-TOF MS methodology
(Figure 2).
Beta-lactamases are biochemically classified into two groups: MBL and serine beta-
lactamase. The MBL, which needs Zn2+ ions at the active site to cleave the beta-lactam
ring, uses metal-ligating amino acids together with polarized water molecules. The serine
beta-lactamase, whose active site includes a serine residue, hydrolyzes the beta-lactam
ring by acylation/deacylation mechanisms [39]. Both of these beta-lactamases carry out
enzymatic cleavage of the beta-lactam ring with the aid of polarized water molecules,
resulting in the disappearance of the original mass peak and the appearance of a new
peak that is 18-Da greater in molecular mass due to the water molecule. The shift peak
is targeted by MALDI-TOF MS for detection. For the analysis, a total of 30–120 min is
needed for incubation of the target bacteria with the beta-lactam drug, with the exception
of OXA-48-type beta-lactamases, which have a slow hydrolysis rate and require up to
240 min of incubation. Commercial software, i.e., the MBT-STAR-BL assay from Bruker,
is available [40]. Of note, the shift spectra are found in a slightly different site by the
selected matrix. For instance, the α-cyano-4-hydroxycinnamic acid matrix eliminated
carbon dioxide and water molecules after hydrolysis, resulting in a shift of −44 m/z for the
modified carbapenem rather than the +18-m/z shift from the additional water molecule [41].
Accordingly, the characteristic shift peaks at the +18 m/z and −44 m/z sites are useful to
identify modified beta-lactams.
Aminoglycoside-modifying enzymes are grouped into three types: acyltransferases,
phosphotransferases, and nucleotidyltransferases [42]. The three transferase reactions
are complex compared to the hydrolysis activity of beta-lactamases, because additional
cofactors, such as ATP, acyl-CoA, NAD+, UDP glucose, and glutathione, are required for
enzymatic activity. Acyltransferases show different preferences for the CoA substrate to
modify different aminoglycosides. Several attempts have been made to establish an equal
mass spectrometry-based assay for the detection of resistance against aminoglycosides.
However, biosynthetic or semisynthetic drugs are often a mixture of different molecules
that vary in their side chains [43], and modifications by aminoglycoside-modifying en-
zymes vary by the moiety introduced to the drug. Mass spectrometric detection of these
modifications has been shown for tobramycin, kanamycin, and neomycin; however, since
this method needs an instrument with high resolution [44], it has never been introduced to
clinical microbiology laboratories using MALDI-TOF MS of a general grade.
4.3. Identification of the Modified Antimicrobial Target
Modified drug targets, which block the antimicrobial action of drugs resulting in AMR,
are another object to detect using the MALDI-TOF MS methodology (Figure 2). Gram-
negative bacterial lipid A is a target of polymyxins, and representative colistin resistance
is conferred by lipid A modification. However, the only accredited and reproducible
procedure to determine susceptibility to colistin is the broth microdilution method, and
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this technique takes days to obtain results and is extremely laborious [45]. As an alternative
method, identification of colistin resistance in Gram-negative bacteria through the detection
of modified lipid A using MALDI-TOF MS was tried [46]. Application of this method to
E. coli [46] and to Acinetobacter spp. [47] presented promising results of a shift peak with
m/z +123 Da for bis-phosphorylated hepta-acyl lipid A with reasonable sensitivity and
specificity. While this method allowed the clear detection of colistin-resistant bacteria, a
few limitations impede its wide use. For instance, the extra step to extract lipid A was
complex [48], and for proper performance, the lipid A analysis needs to be conducted
in negative ion mode in the range of 1000 m/z to 3000 m/z, requiring an instrument of
a higher grade than the MALDI Biotyper of a general grade, such as MALDI-TOF/TOF
MS [46]. Notably, the MALDIxin test, which enables the detection of colistin resistance by
identifying the l-Ara4N- and pEtN-modified lipid A in Gram-negative bacteria using the
MALDI Biotyper Sirius MALDI-TOF MS system, was developed [49].
rRNA methylation is one of the main causes of resistance to antimicrobial drugs
that target the bacterial ribosome, such as macrolides, streptogramins, chloramphenicol,
tetracyclines, and aminoglycosides. Various trials have been carried out to detect rRNA
methylation using MALDI-TOF MS by detecting the +14 Da mass shift from the native
ribosome peak of 999 m/z to a 1013 m/z peak from monomethylation or a 1027 m/z peak
from dimethylation [50]. However, this method needs a difficult step to purify the bacterial
ribosomes, and epoch improvement of the manual is needed for its popular use. Even
though a simplified method was developed through the lipophylization of methylated
ribosomes, it is still not practical for use as a rapid diagnostic method [51].
4.4. Direct Detection of the AMR Determinant
Direct detection of the proteins conferring AMR in bacterial hosts looks ideal, and
the approach has been tried continuously (Figure 2). However, the trials were not always
successful and even the developed method is not widely used in clinical microbiology lab-
oratories due to several difficulties: the large molecular weights of the AMR determinants
are not suitable for detection in the routine range of spectral determination used for species
identification, and the low production of the AMR determinant proteins resulting in low
intensities of the peaks issues indistinguishable peaks which almost contact to the baseline.
Sophisticated protein analysis often requires the top-down strategy.
The first trial of the direct detection was for beta-lactamases produced by transformed
E. coli grown in media with ampicillin [52]. The ideal straightforward approach was not
simple to apply because the bacterial host does not express a large enough amount of the
beta-lactamase gene, which is costly for the bacterial host. Thus, such AMR determinants
often need preinduction to have enough of the protein to detect [53]. Only a few beta-
lactamases, which are produced continuously without induction, presented successful
results for the direct detection of AMR determinants using MALDI-TOF MS. A dominant
penicillinase, TEM-1, which confers resistance to ampicillin in E. coli, was identified at 28972
m/z [52]. Additionally, a plasmid-mediated AmpC beta-lactamase (CMY-2) produced by
clinical E. coli strains was detected by the MALDI-TOF MS method [54]. The molecular
weight of the protein was 39.8 kDa after cleavage of the signal peptide, and the mass peak
was identified at 39800 m/z. From the same approach, K. pneumoniae carbapenemase-2
(KPC-2) was detected at 28544 m/z [54]. A recent publication on the direct detection of the
KPC protein suggested another mass peak at 28718 m/z (Figure 3), but this peak was likely
due to the difference between the dominant subtypes of KPC at a specific region [55].
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range available through the MALDI Biotyper and low resolution out of the usual range, 
alternative targets beyond the AMR determinants have been targeted and are often the 
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Comparing MRSA and MSSA isolates, several peaks indicative of MRSA were able 
to be identified in the mass range of 500–3000 Da, but these peaks have never been further 
identified or characterized [60]. In 2014, a single peak at 2415 m/z was identified from a 
phenol extraction of MRSA isolates and was proposed to be an MRSA-specific phenol-
soluble modulin (PSM)-mec peptide [61]. However, the 2415-m/z peak was identified in 
only the MRSA isolates carrying the SCCmec types II and III but not in the isolates harbor-
ing the SCCmec types I, IV, or XI, which is a great limitation as a biomarker to detect MRSA 
[62,63]. Similarly, a KPC-carrying plasmid-associated biomarker at 11109 m/z has been 
proposed for the identification of KPC-producing Enterobacterales [64]. However, blaKPC-
carrying plasmid-associated biomarkers have very limited use in the detection of KPC-
Figure 3. Identification of the KPC producer by using the KPC peak at 28718 m/z. Mass spectra were obtained from the
lysates of drug-suscep ible (upper) and carbapenem-resistant (bottom) E. coli conferred by the KPC-2 enzyme. A KPC peak
is present d near the theoretical molecular weight of the KPC-2 polypeptide, with g ay vertical line, at 28718.13 m/z.
Porin defects, which are commonly associated with AMR or reduced antimicrobial
susceptibility in Gram-negative bacteria, have been other targets to detect by MALDI-
TOF MS [56]. Loss of OmpK36 in K. pneumoniae was detected by the method through
disappearance of the peaks at 38000 m/z and 19000 m/z [57]. Overproduction of the efflux
system is associated with multidrug resistance in Gr m-negative bacteria and is a good
subject to detect by MALDI-TOF MS. However, since this technique is not appropriate to
quantify the protein accurately, the approach was not fruitful with MALDI-TOF MS but
was possible with liquid chromatography (LC)-MS, such as LC coupled to an electrospray
triple quadrupole MS [58].
4.5. Biomarkers That Are Coexpressed Proteins with AMR Deter inants
As described in the above section, most of the proteins conferring AMR in the bacterial
host have large molecular weights that are above the mass range of routine MALDI-TOF
MS for species identification, which is between 2–20 kDa: the penicillin-binding protein
2a in S. aureus, approximately 76.4 kDa; beta-lactamases that are produced by Enterobac-
terales, such as TEM, SHV, CTX-M, and AmpC, approximately 30 kDa; 16S ribosomal
methyltransferases conferring resistance to aminoglycosides in Gram-negative bacteria,
such as ArmA and RmtA, approximately 30 kDa; and 23S ribosomal methyltransferases
conferring macrolide-lincosamide-streptogramin B antimicrobials in Gram-positive bac-
teria, such as ErmA, ErmB, and ErmC, approximately 29 kDa [59]. Due to the narrow
range available through the MALDI Biotyper and low resolution out of the usual range,
alternative targets beyond the AMR determinants have been targeted and are often the
protein that is coproduced in the antimicrobial-resistant bacteria (Figure 2).
Comparin MRSA and MSSA isolates, several peaks i dicative of MRSA were able to
be identified in the mass r nge of 500–3000 D , but these peaks have never been further
identified or characterized [60]. In 2014, a single peak at 2415 m/z was identified from
a phenol extraction of MRSA isolates and was proposed to be an MRSA-specific phenol-
soluble modulin (PSM)-mec peptide [61]. However, the 2415-m/z peak was identified
in only the MRSA isolates carrying the SCCmec types II and III but not in the isolates
harboring the SCCmec types I, IV, or XI, which is a great limitation as a biomarker to detect
MRSA [62,63]. Similarly, a KPC-carrying plasmid-associated biomarker at 11109 m/z has
been proposed for the identification of KPC-producing Enterobacterales [64]. However,
blaKPC-carrying plasmid-associated biomarkers have very limited use in the detection of
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KPC-producing bacteria, since the blaKPC gene is observed in divergent plasmids and
sometimes in chromosomes [65–67].
5. Future Aspects
Through recent advances, MALDI-TOF MS-based approaches have exhibited consider-
able potential for the rapid, simple, and cost-effective diagnosis of AMR in microorganisms
of clinical importance (Table 1). Present limitations of detection, especially when using the
most common entry-level instrument for MALDI-TOF MS, include low resolution above
and below the routine range of spectral determination used for species identification, and
low-level expression of the AMR-determining proteins. However, varied approaches have
been attempted to overcome these limitations and simple sample-processing methods and
novel matrices are being developed to defeat the defects. Few exceptional discrepancies
between the MALDI-TOF MS-based AMR determination and methods based on the AMR
phenotypes of bacteria have been found, such as AMR conferred by overproduction of
certain efflux systems [68] or by complete loss of the drug target [69], and applications of
the MALDI-TOF MS method to a large set of clinical samples will help improvements in
the method.
Table 1. MALDI-TOF MS-based rapid diagnostic methods for AMR.








DoT-MGA 2 (inv. 3)
[22,24,25,70,71]
ID of the AMR
clonal group Clone-specific spectra Methicillin (MRSA) ClinProtTools (Bruker) [72]
ID of the modified
antimicrobial drug









ID of the modified
antimicrobial target
Shift peak of the
modified drug target Colistin MALDIxin test (inv.) [49,75]
Direct detection of the




Biomarker detection Protein-specific peak Carbapenems ClinProtTools (Bruker) [64,76]
1 AUC, area under curve. 2 DoT-MGA, Direct-on-Target Microdroplet Growth Assay. 3 inv., under investigation.
Beyond the rapid AMR detection, the MALDI-TOF MS methodology is able to have
wider applications owing to its simple operation and availability for high-throughput sys-
tems. For instance, this methodology has been shown to be useful for the detection of pro-
tein toxins, such as staphylococcal enterotoxin B, botulinum neurotoxins,
Clostridium perfringens epsilon toxin, and Shiga toxin, which can be potential bioterrorism
agents when they are delivered via an aerosol route [77,78]. In addition, the identification
of multiple bacteria in complex polymicrobial mixtures [79] is another aspect we expect to
be developed through this methodology.
Some manipulations are needed to enhance the applications of MALDI-TOF MS for
AMR diagnostics. Primarily, the instrument quality is diverse, those with high specifica-
tions are very expensive, and unfortunately, the spectra produced by instruments with
different specifications are often incompatible. Concentrated research and development
based on continuous trials is needed to overcome the issue, especially to use the top-down
approach to identify specific markers indicating the AMR [55,80].
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6. Conclusions
Thanks to the development of the MALDI-TOF MS technique, the identification of
organisms causing infectious diseases is no longer a time-determining step for optimizing
a treatment strategy. In addition to microorganism species identification, this methodology
can also be the leading application for the identification of AMR in bacterial pathogens in
clinical settings. In particular, its great speed and simple application would be the most
suitable for endemic AMR clinical strains in specific settings, i.e., MRSA, VRE, carbapenem-
resistant A. baumannii and P. aeruginosa, and ESBL-, AmpC-, and carbapenemase-producing
Enterobacterales. More effort should be made to develop detection methods for drug-
resistant bacterial pathogens.
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